These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38197567)

  • 1. Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
    Gronlund JK; Veigaard C; Juhl-Christensen C; Skou AS; Melsvik D; Ommen HB
    Eur J Haematol; 2024 Apr; 112(4):601-610. PubMed ID: 38197567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
    Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
    J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of NPM1 Mutations in Acute Myeloid Leukemia by using Drop-Off Droplet Digital PCR and its Clinical Application.
    Jin Y; Xu ZJ; Yu D; Xia PH; Yao DM; Yuan Q; Li T; Xiang HL; Ma JC; Wen XM; Lin J; Qian J
    Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
    Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
    Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.
    Winters AC; Minhajuddin M; Stevens BM; Major A; Bosma G; Abbott D; Miltgen N; Yuan J; Treece AL; Siegele BJ; Ewalt MD; Gutman JA; Jordan CT; Pollyea DA
    Haematologica; 2024 Jun; 109(6):1766-1778. PubMed ID: 38105738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
    Marumo A; Wakita S; Morita K; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Uoshima N; Kobayashi Y; Kawata E; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Kubota Y; Kimura S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Date K; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Ohashi K; Kanda Y; Yamaguchi H
    Int J Hematol; 2022 Aug; 116(2):199-214. PubMed ID: 35377134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
    Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
    Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.
    Stanojevic M; Grant M; Vesely SK; Knoblach S; Kanakry CG; Nazarian J; Panditharatna E; Panchapakesan K; Gress RE; Holter-Chakrabarty J; Williams KM
    Front Immunol; 2022; 13():999298. PubMed ID: 36248870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis.
    Pettersson L; Chen Y; George AM; Rigo R; Lazarevic V; Juliusson G; Saal LH; Ehinger M
    Leuk Lymphoma; 2020 Sep; 61(9):2168-2179. PubMed ID: 32425124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of NPM1 Mutation in Acute Myeloid Leukemia by Droplet Digital PCR and Its Clinical Application Value].
    Jin Y; Wang SS; Xia PH; Yuan Q; Xiao GF; Lin J; Leng JY; Ma YJ; Qian J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):653-658. PubMed ID: 35680787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
    Dillon R; Hills R; Freeman S; Potter N; Jovanovic J; Ivey A; Kanda AS; Runglall M; Foot N; Valganon M; Khwaja A; Cavenagh J; Smith M; Ommen HB; Overgaard UM; Dennis M; Knapper S; Kaur H; Taussig D; Mehta P; Raj K; Novitzky-Basso I; Nikolousis E; Danby R; Krishnamurthy P; Hill K; Finnegan D; Alimam S; Hurst E; Johnson P; Khan A; Salim R; Craddock C; Spearing R; Gilkes A; Gale R; Burnett A; Russell NH; Grimwade D
    Blood; 2020 Feb; 135(9):680-688. PubMed ID: 31932839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.
    Li EW; Tran NYK; McCulloch D; Krigstein M; Catalano A; Othman J; Abadir E; Smith C; Iland H
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.